Dana Huskens

Dr. Dana Huskens

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Blood Reviews
Verified
Journal Article
Closed access
YSYaqiu Sang
Yaqiu Sang
MRMark Roest
Mark Roest
BLBas de Laat
Bas de Laat
PGPhilip G. de Groot
Philip G. de Groot
DHDana Huskens
Dana Huskens

1 February 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DHDana Huskens
Dana Huskens
YSYaqiu Sang
Yaqiu Sang
JKJoke Konings
Joke Konings
LVLisa van der Vorm
Lisa van der Vorm
BLBas de Laat
Bas de Laat
MRMark Roest
Mark Roest
Platelet function testing with flow cytometry has additional value to existing platelet function testing for diagnosing bleeding disorders, monitoring anti-platelet therapy, transfusion medicine and prediction of thrombosis. The major challenge is to use this technique as a diagnostic test. The aim of this study is to standardize preparation, optimization and validation of the test kit and to determine reference values in a population of 129 healthy individuals. Platelet function tests with 3 agonists and antibodies against P-selectin, activated αIIbβ3 and glycoprotein Ib (GPIb), were prepared and stored at -20°C until used. Diluted whole blood was added and platelet activation was quantified by the density of activation markers, using flow cytometry. Anti-mouse Ig κ particles were included to validate stability of the test and to standardize results. Reference intervals were determined. Blood stored at room temperature (RT) for up to 4h after blood donation and preheated/tested at 37°C resulted in stable results (%CV<10%), in contrast to measuring at RT. The intra-assay %CV was <5%. Incubation of anti-mouse Ig κ particles with antibodies stored for up to 12 months proved to give a stable fluorescence. The inter-individual variation measured in the 129 individuals varied between 23% and 37% for P-selectin expression and αIIbβ3 activation, respectively. The current study contributes to the translation of flow cytometry based platelet function testing from a scientific tool to a diagnostic test. Platelet function measurements, using prepared and stored platelet activation kits, are reproducible if executed at 37°C. The reference ranges can be validated in clinical laboratories and ongoing studies are investigating if reduced platelet reactivity in patients with bleeding complications can be detected.

Verified
Journal Article
Open access
PDF file
AMAdam Miszta
Adam Miszta
DHDana Huskens
Dana Huskens
DDDemy Donkervoort
Demy Donkervoort
MRMolly J. M. Roberts
Molly J. M. Roberts
AWAlisa Wolberg
Alisa Wolberg
DBDe Laat Bas
De Laat Bas
Fibrinolysis is an important process in hemostasis responsible for dissolving the clot during wound healing. Plasmin is a central enzyme in this process via its capacity to cleave fibrin. The kinetics of plasmin generation (PG) and inhibition during fibrinolysis have been poorly understood until the recent development of assays to quantify these metrics. The assessment of plasmin kinetics allows for the identification of fibrinolytic dysfunction and better understanding of the relationships between abnormal fibrin dissolution and disease pathogenesis. Additionally, direct measurement of the inhibition of PG by antifibrinolytic medications, such as tranexamic acid, can be a useful tool to assess the risks and effectiveness of antifibrinolytic therapy in hemorrhagic diseases. This review provides an overview of available PG assays to directly measure the kinetics of plasmin formation and inhibition in human and mouse plasmas and focuses on their applications in defining the role of plasmin in diseases, including angioedema, hemophilia, rare bleeding disorders, COVID-19, or diet-induced obesity. Moreover, this review introduces the PG assay as a promising clinical and research method to monitor antifibrinolytic medications and screen for genetic or acquired fibrinolytic disorders.

1 January 2016 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
JKJoke Konings
Joke Konings
RKRomy M. W. Kremers
Romy M. W. Kremers
SBSaartje Bloemen
Saartje Bloemen
ESEvelien Schurgers
Evelien Schurgers
ASAnna Selmeczi
Anna Selmeczi
JRJasper A. Remijn
Jasper A. Remijn
Summary: Physical exercise is recommended for a healthy lifestyle. Strenuous exercise, however, may trigger the haemostatic system, increasing the risk of vascular thrombotic events and the incidence of primary cardiac arrest. Our goal was to study the effects of strenuous exercise on risk factors of cardiovascular disease. Blood was collected from 92 healthy volunteers who participated in the amateur version of the protour Amstel Gold cycling race, before and directly after the race. Thrombin generation showed a shortening of the lag time and time to peak and an increase of the velocity index. Interestingly, the endogenous thrombin potential measured in plasma decreased due to reduced prothrombin conversion. Platelet reactivity increased and this effect was stronger in men than in women. Lower fibrinogen and higher D-dimer levels after exercise indicated higher fibrin formation. On the other hand, fibrinolysis was also elevated as indicated by a shortening of the clot lysis time. Exercise activated the endothelium (von Willebrand factor (VWF) and active VWF levels were elevated) and the immune system (concentrations IL-6, IL-8, MCP-1, RANTES and PDGF increased). Additionally, an increased cardiac troponin T level was measured post-exercise. Strenuous exercise induces a temporary hyperreactive state in the body with enhanced proand anticoagulant responses. As strenuous exercise has a more pronounced effect on platelet function in male subjects, this gives a possible explanation for the higher incidence of sudden cardiac death during exercise compared to women. This trial is registered at www.clinicaltrials.gov as NCT02048462.

1 September 2020 in Respiratory Medicine
Verified
Journal Article
Closed access
LVLisa N. van der Vorm
Lisa N. van der Vorm
LLLi Li
Li Li
DHDana Huskens
Dana Huskens
JHJanine J.J. Hulstein
Janine J.J. Hulstein
MRMark Roest
Mark Roest
SSSami O. Simons
Sami O. Simons

4 April 2018 in TH Open
Verified
Journal Article
Open access
PDF file
LVLisa N. van der Vorm
Lisa N. van der Vorm
JRJasper A. Remijn
Jasper A. Remijn
BLBas de Laat
Bas de Laat
DHDana Huskens
Dana Huskens
Plasmin is the major fibrinolytic protease responsible for dissolving thrombi by cleavage of its primary substrate fibrin. In addition, emerging evidence points to other roles of plasmin: (1) as a back-up for ADAMTS13 in proteolysis of ultra-large von Willebrand factor (VWF) multimers and (2) as an activator of platelets. Although the molecular mechanisms of fibrinolysis are well defined, insights on the effects of plasmin on VWF and platelets are relatively scarce and sometimes conflicting. Hence, this review provides an overview of the literature on the effects of plasmin on VWF multimeric structures, on VWF binding to platelets, and on platelet activation. This information is placed in the context of possible applications of thrombolytic therapy for the condition thrombotic thrombocytopenic purpura.